Regeneron Immunotherapy Combo Comes up Short in Melanoma Trial

Regeneron sinks as Phase 3 skin cancer treatment trial fails

The company faces a wave of price target cuts and a steep stock decline following the late-stage clinical trial failure of its experimental melanoma combination therapy.

Regeneron immunotherapy combo comes up short in melanoma trial

A two-drug regimen of Regeneron’s fianlimab and Libtayo didn’t significantly outperform Keytruda in a late-stage study, a finding that surprised Wall Street analysts and wiped out billions in market value.

Regeneron drops after skin cancer treatment misses late-stage trial goal

The drugmaker's fianlimab-cemiplimab ⁠combination ‌did not reach statistical ⁠significance in improving progression-free survival (PFS).

Regeneron Sinks After Late-Stage Melanoma Trial Failure

Regeneron Pharmaceuticals Inc. said a key late-stage melanoma study failed, adding to a series of challenges for the US biotech. The shares plunged in premarket trading.

Regeneron Sinks 10% on Failed Phase 3 Melanoma Trial. What Comes Next for REGN Stock.

Regeneron stock sinks as fianlimab Phase 3 trial fails to meet primary endpoint. But RBC continues to see significant upside in REGN shares from here.

Regeneron Opens Lower After Cancer Trial Setback

Regeneron shares dropped 11.8% in premarket trading Monday after its melanoma drug combo failed to meet the main goal in a late-stage trial. The high-dose fianlimab and cemiplimab combination showed a median progression-free survival of 11.5 months versus 6.4 months for Merck’s Keytruda, but missed statistical significance. Citi downgraded the stock and cut its price target to $700. Regeneron shares closed Friday at $698.25. The post Regeneron O…